Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Regardless of whether the selling is done, when the buying starts here it will go back up very quickly…. I just bought a few and that made a difference already.
This is the last timescale I have seen
https://www.weare121.com/121mininginvestment-cape-town/rainbow-rare-earths/
Low volumes, significant size buy back and hopefully the start of the buy back has coincided with the end of Invesco reducing its stake.
Seems there was no buy back yesterday, would explain the sharp drop yesterday
Good to see Kiln 3 still expected in Q2:
https://www.weare121.com/121mininginvestment-cape-town/bushveld-minerals/
And even if Chinas steel production goes down - so will it’s vanadium production
This could also put a rocket under the vanadium price - look at the impact on the uranium price earlier this year when the Sprott trust was launched.
Courtesy of @lovelyboy on the rbw board:
https://www.mckinsey.com/industries/metals-and-mining/our-insights/the-raw-materials-challenge-how-the-metals-and-mining-sector-will-be-at-the-core-of-enabling-the-energy-transition?cid=other-eml-alt-mip-mck&hdpid=d1d9d3ec-f753-4eaf-b020-1b2640973372&hctky=11776925&hlkid=e4f752c13f7b4d05981ea42e295533ad
It’s based on the aim 100 index which is periodically reviewed based on market cap. MTR are a long way from inclusion in that index. You tried to create the suggestion that Simon Thompson had stopped tipping mtr which is misleading.
A rather misleading post Richie. That aim top one hundred was based on company size - mtr would not come near inclusion based on its capitalisation. Nothing to do with Simon Thompson, he has consistently been tipping mtr as recently as last August.
Metal tiger still expecting news before Christmas….
https://twitter.com/metaltigerplc/status/1468940085009788931
About 9 mins in
Investors would be forgiven for thinking the metaphorical Bushveld Minerals (BMN) bus is parked in the same spot it was a year ago.
The mining company, which produces steel ingredient vanadium, is trading at the same price that it was at its last half-year results announcement, after a sharp rise earlier in the year, and has again posted losses in both cash profits and the bottom line.
These were exacerbated by a stronger South African rand (which knocked $7m, or £5.4m, from its Ebitda) and mining challenges that brought down production and increased costs.
A 9 per cent sales increase was thanks to the higher vanadium price for the six months to 30 June, which climbed from $24 per kilogramme last year to $29/kg in the period.
Bushveld chief executive Fortune Mojapelo said recent months had seen improvements in production, and these would carry through the second half. A big investment in the Vanchem mine refurbishment will see output climb significantly next year, he added, with the company’s vanadium production capacity set to climb from around 3,500 tonnes (t) this year to over 5,000t on an annualised basis.
This will cost $18m, funded through a $30m ‘production financing agreement’ with industry lender Orion Mine Finance from last year, which agreed it could be shifted from its other mine.
Broker Peel Hunt sees Bushveld reporting a low cash profit this year of £6.5m, before this skyrockets to £79m in 2022. Looking again to the next year for big catalysts is not good practice, but Bushveld should deliver this time. Buy.
Thanks Bella - that certainly explains some of the posts on this forum
Absolutely Amg - why else emphasize that the AffiDX® antigen test has been developed in the UK, and is based on UK technology and manufactured in the UK.
That’s hardly going to help our European sales these days…..
Amg - she actually calls it a U.K. made test and describes it as a real milestone on the progressive journey of the UK diagnostics and life sciences industry.
Dave I think you may have left out the best reason why it could still be us - we now finally actually manufacture real tests….
And I agree with your point about odx - I suspect that at that time the government were simply trying to find out from odx how difficult it might be to use their equipment to produce one of the established tests - as a theoretical possibility only.
In all the finger pointing and accusations of government corruption (unlikely IMO) and incompetency (very likely) we perhaps forget that whilst avacta didn’t manufacture any tests we didn’t give the government many options to actually choose us.
Forgot link https://questions-statements.parliament.uk/written-questions/detail/2021-06-18/18511
Apologies if already posted:
To ask the Secretary of State for Health and Social Care, when the Government plans announce its choice of British lateral flow test after the signing of contracts in March 2021 with Omega Diagnostics and Global Access Diagnostics in order to meet the target of having the majority of UK lateral flow tests produced in the UK.
ANSWER: The Government continues to explore different operating models to make best use of the capacity created in the United Kingdom diagnostics manufacturing industry. There are a number of ongoing conversations between Global Access Diagnostics, Omega and third party test developers which we hope will provide opportunities to further increase UK manufacturing output of lateral flow tests.
Sounds to me that GAD are using a third party contractor for part of their operations and ODX are not. I’m not convinced of the significance of these contracts in terms of the identity of the test developer - but it is significant in that matters are clearly still progressing and possibly about to reach a conclusion.
Brilliant post Pottery, so Mologic/ODX is best in class only when benchmarking against second rate PCR equipment!